Procept Biorobotics (PRCT) Q4 2025: Handpiece ASP Jumps 9% as Pricing Discipline Resets Growth Trajectory

2026-02-25 | By EarningsIQ Research

Procept Biorobotics’ Q4 marked a decisive operational reset as management eliminated bulk handpiece discounts, driving a 9% ASP uplift and aligning sales with actual procedure volumes. The resulting near-term revenue impact is offset by improved price discipline and a more predictable business model, positioning the company for sustainable growth and profitability. Investors now face a transition period with front-loaded disruption but a clearer path to margin expansion and scalable execution in 2026 and beyond.

Summary

• Pricing Reset Drives Structural Change: Handpiece sales now track procedures, improving predictability and margin visibility.
• Commercial Realignment Disrupts Near Term: Sales force overhaul and launch team creation create temporary headwinds as relationships reset.
• Profitability Path Becomes Clearer: Margin discipline and focused execution set up positive EBITDA by Q4 2026.

Performance Analysis

Q4 2025 marked a watershed moment for Procept Biorobotics as leadership implemented a deliberate shift in commercial practices, ending the legacy model of bulk handpiece discounts and aligning unit sales directly with procedure volumes. This move, while producing a near-term revenue shortfall and a 450 basis point gross margin compression, resulted in a 5% sequential increase in handpiece average selling price (ASP) and a structurally healthier revenue mix. US procedure growth remained robust at 69% YoY, but handpiece unit sales dropped to 80% of procedures, reflecting the inventory destocking and end-of-quarter discount elimination.

International revenues grew 25% YoY, while US system placements reached an all-time high, expanding the installed base by 42%. Operating expenses increased 22% YoY as the company invested in commercial expansion and clinical initiatives, with adjusted EBITDA loss widening to $19 million. Despite these pressures, the company exited the year with $285 million in cash, providing ample runway to support its multi-year growth and margin ambitions.

• Margin Headwind from Field Action: A one-time voluntary field upgrade accounted for 240 basis points of Q4 margin pressure.
• Inventory Correction Drives Revenue Mix Shift: Ending bulk discounts reduced handpiece sales but increased ASP to $3,340, up 9% YoY.
• Operating Investment Accelerates: OpEx rose with expansion in sales, clinical trials, and platform innovation.

The quarter’s results reflect a purposeful tradeoff: near-term disruption in favor of long-term business quality, with management signaling confidence in a more stable, margin-accretive growth model.

Executive Commentary

Strategic Positioning

1. Commercial Model Overhaul

Procept’s commercial team was reorganized into integrated regional structures, with sales and clinical functions now reporting to a single leader. This is designed to improve accountability, accelerate procedure growth, and ensure customer success. The creation of a dedicated launch team, staffed by top performers, aims to standardize new system activation and reduce time-to-value for customers.

2. Pricing Discipline as Margin Lever

Eliminating end-of-quarter bulk handpiece discounts fundamentally shifts the revenue model, aligning sales with true procedure volumes and raising ASPs. Management expects the handpiece-to-procedure sales ratio to remain near 1:1, driving sustainable margin expansion and revenue predictability. This move also reconditions customer behavior and sets a new baseline for future growth.

3. Path to Profitability and Scale

Despite the near-term hit, Procept’s financial guidance signals a clear route to positive EBITDA by Q4 2026, underpinned by higher ASPs, a growing installed base, and tighter OpEx control. The company expects gross margin to rebound to 65% in 2026, absorbing higher tariff expenses, while OpEx growth moderates to 17% YoY as commercial investments peak.

4. Market Development and Share Capture

While still early in the BPH surgical market, Procept is shifting from a pure system placement focus to share capture and procedure growth. Management highlights substantial headroom, with less than 10% penetration in a 400,000-procedure annual market, and is investing in clinician and patient education to accelerate adoption of aquablation, its robotic BPH therapy.

5. Launch Execution as Growth Multiplier

The new launch team model is expected to halve the time from system order to first ten procedures, a critical metric for system utilization and downstream consumable pull-through. Early pilot data supports this approach, and management is rolling out the model company-wide in 2026.

Key Considerations

Procept’s Q4 pivot is a textbook example of trading short-term revenue for long-term business quality, with execution risk in the transition phase but a structurally improved model on the other side.

Key Considerations:

• Handpiece Sales Now Mirror Procedures: The shift to 1:1 handpiece-to-procedure alignment removes inventory-driven revenue volatility and clarifies true demand signals.
• Sales Force Disruption Is Transient: Leadership expects temporary headwinds as new account relationships are built, with benefits accruing in H2 2026.
• Margin Expansion Hinges on ASP Discipline: Sustained price integrity is central to the company’s path to profitability and will be tested as customers adjust to new norms.
• Installed Base Growth Remains Robust: System placements and greenfield opportunities continue, supporting future consumable growth and market penetration.
• Patient and Clinician Education Is Underway: Targeted initiatives aim to build awareness and drive share gains in a large, under-penetrated BPH market.

Risks

Execution risk is elevated as Procept navigates the transition to a new commercial model, with potential for slower-than-expected sales force ramp and customer adjustment to higher handpiece prices. Tariff headwinds and increased OpEx investment could pressure margins if procedure growth does not accelerate as planned. Competitive dynamics, particularly from alternative BPH therapies and payer coverage shifts, remain ongoing watchpoints.

Forward Outlook

For Q1 2026, Procept guided to:

• 12,000 to 12,800 US procedures (29–37% YoY growth)
• $79 to $82 million in total revenue (14–19% YoY growth)

For full-year 2026, management guided:

• $390 to $410 million in total revenue (27–33% YoY growth)
• Gross margin of approximately 65%, absorbing $5–6 million in tariffs
• Operating expenses of $350 million (17% YoY increase)
• Positive EBITDA in Q4 2026 at both ends of the revenue range

Management highlighted:

• Handpiece ASP expected to reach $3,500 in 2026, up 9% YoY
• Procedure growth to accelerate in H2 as commercial changes take hold

Takeaways

The quarter marks a structural inflection for Procept, with near-term turbulence giving way to a more scalable and profitable model.

• Revenue Predictability Improves: Aligning handpiece sales with procedures removes inventory-driven noise and supports clearer demand visibility.
• Margin and Profitability Levers Activated: ASP discipline and OpEx control underpin management’s confidence in a positive EBITDA exit rate for 2026.
• Sales Force Maturity Key to H2 Acceleration: Investors should monitor the pace of sales force ramp and launch team impact as leading indicators for sustainable growth.

Conclusion

Procept Biorobotics’ Q4 was a reset quarter, prioritizing long-term margin expansion and sustainable growth over short-term revenue maximization. The company’s disciplined approach to pricing and commercial execution sets a higher-quality foundation, but successful navigation of the transition period will be critical to unlocking the full potential of its BPH platform.

Industry Read-Through

Procept’s experience highlights a broader medtech trend: shifting away from volume-driven discounting toward price discipline and true demand alignment. The move to synchronize consumable sales with procedures offers a playbook for other device firms seeking revenue predictability and margin expansion. Sales force realignment and dedicated launch teams underscore the importance of operational focus in scaling novel platforms. Investors in the surgical robotics and urology markets should watch for similar transitions across peers, as pricing integrity and launch execution become increasingly central to sustainable growth narratives.

PRCT Health Care Medical Devices Robotics Margin Expansion Pricing Commercial Execution BPH Therapy